Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma
Open Access
- 21 October 2019
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 95 (1) , E8-E10
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaAdvances in Therapy, 2018
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology, 2015
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Human CD38: a glycoprotein in search of a functionImmunology Today, 1994
- Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cellsHuman Immunology, 1984